Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 9Genitourinary 5CNS 3Breast 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Papillomavirus Infections 1Nasopharyngeal Neoplasms 1

Interventions

Cisplatin 620pembrolizumab 323Radiotherapy 319Cetuximab 275Docetaxel 221Radiotherapy, Intensity-Modulated 210Carboplatin 197Fluorouracil 196Paclitaxel 159Nivolumab 138Gemcitabine 124Magnetic Resonance Spectroscopy 94Radiation 85Drug Therapy 77Capecitabine 76toripalimab 75Surgical Procedures, Operative 62durvalumab 60Biopsy 52Cyclophosphamide 50Chemoradiotherapy 47camrelizumab 46Specimen Handling 46Erlotinib Hydrochloride 46Radiosurgery 45130-nm albumin-bound paclitaxel 44Standard of Care 43tislelizumab 42Platinum 41Bevacizumab 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × infigratinib × Head & Neck × Clear all
NCT02706691 2019-04-16

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

University of Chicago

Phase 2 Terminated
1 enrolled 8 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡